Metformin extended release formulation
Pro Research Analysisby 
Searched over 220M research papers
Extended-Release Metformin Formulation: Key Ingredients and Methods
Extended-release (ER) formulations of metformin are designed to release the drug slowly over time, improving blood sugar control and patient compliance in type 2 diabetes. The most common approach uses a combination of hydrophilic polymers, such as hydroxypropyl methylcellulose (HPMC), and hydrophobic carriers like stearic acid or ethylcellulose to control the drug’s release rate Nanjwade2011Satyanarayana2012Rajesh2012+1 MORE. The concentration and type of polymer directly affect how long the drug is released, with higher amounts of HPMC or similar agents leading to slower, more sustained release Satyanarayana2012Rajesh2012Kakaei2024.
Manufacturing Techniques for Metformin ER Tablets
Two main manufacturing methods are used: melt granulation and direct compression. Melt granulation, which involves melting the hydrophobic carrier to bind the ingredients, has been shown to be more effective at extending drug release compared to direct compression Nanjwade2011Pawar2019. Wet granulation is also commonly used, especially when incorporating polymers like HPMC or sodium carboxymethyl cellulose, to ensure uniform distribution and tablet integrity Satyanarayana2012Rajesh2012Priyadarshini2016.
Alternative ER Formulations: Suspensions and Gastroretentive Systems
Beyond tablets, extended-release metformin can be formulated as oral suspensions using coated pellets. These suspensions are especially useful for patients who have difficulty swallowing tablets. The use of ethylcellulose as a coating agent and xanthan gum as a suspending agent helps maintain extended drug release and uniformity in the suspension Patil2024Satterwhite2021. Gastroretentive systems, which use polymers like methacrylamide-g-gellan and tamarind seed gum, are designed to keep the tablet in the stomach longer, further prolonging drug release and improving absorption .
Drug Release Kinetics and Bioequivalence
The release of metformin from ER formulations typically follows non-Fickian or anomalous transport kinetics, meaning both diffusion and polymer relaxation contribute to the release profile Nanjwade2011Priyadarshini2016. Achieving bioequivalence with commercial products like Glucophage XR requires careful selection and optimization of polymer types and concentrations, as well as in vitro and in vivo testing to match the reference product’s pharmacokinetic profile Nanjwade2011Kakaei2024Zhang2021.
Clinical Advantages of Extended-Release Metformin
ER metformin offers several clinical benefits over immediate-release forms. It improves gastrointestinal tolerability, allows for once-daily dosing, and maintains similar glucose-lowering efficacy and weight-neutral effects. Patients who experience GI side effects with immediate-release metformin often tolerate the ER formulation better, which can lead to improved adherence and better long-term glycemic control . ER formulations are available in both branded and generic forms, and new oral suspension options further expand accessibility for patients with swallowing difficulties Satterwhite2021Jabbour2011.
Conclusion
Extended-release metformin formulations use a combination of hydrophilic and hydrophobic polymers, with manufacturing methods like melt granulation and wet granulation optimizing sustained drug release. These formulations improve patient adherence, reduce GI side effects, and offer flexible dosing options, making them a valuable choice for managing type 2 diabetes Nanjwade2011Satyanarayana2012Rajesh2012+7 MORE.
Sources and full results
Most relevant research papers on this topic